Navigation Links
Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
Date:1/29/2013

PASADENA, Calif., Jan. 29, 2013 /PRNewswire/ -- Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company has been in negotiations with an International Bio-Tech Partner in the HIV cure technology sector for joint advanced Research & Development and the partner has agreed to provide the necessary funding for the USA Clinical Trials phases to ultimately achieve FDA approval for the medicines.

A senior spokesperson for Immunotech further added, the terms while yet to be fully determined include some exclusive rights for the International partner for use and distribution of the vaccines in several countries where the equivalent of FDA approval is not required and can be distributed and administered labeled as an "Experimental Drug". This process will help accelerate the clinical trials results.

Pursuant to significantly positive results with its patient population targeting full blown AIDS patients, the company has completed numerous clinical contracts with Mexican hospitals to initiate a full blown effort of clinical trial protocol preparation for its HIV/AIDS Vaccine drug candidate. The successful outcome of these efforts will eventually provide the necessary regulatory means for its product's registration approval in the Republic of Mexico and eventually open a venue to most of the central and South American markets.

Further information can be obtained from www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Contact: Harry Zhabilov
President and Chief Science Officer
Telephone: 818-409-9091
Investor Relations
IR@immunotechlab.com

Contact
CSNNewswire.com
310-467-6521
info@csnnewswire.com


'/>"/>
SOURCE Immunotech Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
2. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
3. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
4. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
5. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
6. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
7. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
8. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
9. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
10. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
11. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... updated financial guidance for 2016 on Thursday, December 15, ... that day with the investment community and media to ... conference call will begin at 10 a.m. ET. Investors, ... webcast of the conference call through a link that ...
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, cloud-based ... named the best Sales Team of 2016 as part of the 2016 SIIA ... the Software & Information Industry Association (SIIA), the principal trade association for the ...
(Date:11/30/2016)... ... 2016 , ... The Fertility Centers of New England ... Infertility Center of Excellence. The Cigna Center of Excellence recognizes participating infertility centers ... be designated a Cigna Infertility Center of Excellence," said Fertility Centers of New ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... 2016 , ... In recent policy debates, increasing costs of ... and system stakeholders in many states. To help them understand this growth, today ... Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a policymaker or ...
Breaking Medicine News(10 mins):